The European Commission has granted marketing authorisation to Sandoz biosimilar Hyrimoz for use in all indications including rheumatoid arthritis plaque psoriasis Crohn's disease uveitis and ulcerative colitis.The Novartis subsidiary Sandoz gained approva...
↧